RMD Open

is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 6.2
Citescore: 7.7
All metrics >>

RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

It is an online only open access journal that aims to provide rapid publication of research through a continuous publication model. All submitted content is subject to peer review prior to publication. Published work is free to read.

RMD Open is an official journal of EULAR.

Listen to the ARD and RMD Open podcast and subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify.

You can keep up with the latest news via Twitter and Facebook.

Editorial team

Current Issue

Latest Articles

Rheumatoid arthritis:

Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment

29 September 2023

Imaging:

HLA-B27 status and inflammatory MRI lesions of the sacroiliac joints: a post hoc analysis in patients without axial spondyloarthritis

22 September 2023

Osteoarthritis:

Use of non-surgical treatments on the journey to knee replacement in patients with knee osteoarthritis: a 10-year population-based case-control study

22 September 2023

Osteoarthritis:

Comparative effectiveness of pharmacological interventions for hand osteoarthritis: a systematic review and network meta-analysis of randomised trials

21 September 2023

Psoriatic arthritis:

Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities

21 September 2023

Video Abstract

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

20 February 2023

Conclusion: In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.

Find out more

EULAR Congress 2023

The 2023 EULAR Congress took place on 31 May – 03 June in Milan, Italy as a hybrid event.

The aim of the European Congress of Rheumatology is to provide a forum of the highest standard for scientific (both clinical and basic), educational and social exchange between professionals involved in rheumatology, liaising with patient organisations, in order to achieve progress in the clinical care of people with rheumatic diseases.

The abstracts from the congress have been published in ARD and are free to read.

Visit the congress website for more information